• If you are having problems logging in please use the Contact Us in the lower right hand corner of the forum page for assistance.

Organophosphates neurotoxic in many ways.

Kathy

Well-known member
Joined
Feb 11, 2005
Messages
837
Location
Home on the Range, Alberta
Toxicol Appl Pharmacol. 2005 Sep 1;207(2):112-24.

Chlorpyrifos exerts opposing effects on axonal and dendritic growth in primary neuronal cultures.

Howard AS, Bucelli R, Jett DA, Bruun D, Yang D, Lein PJ.
Department of Environmental Health Sciences, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.

Evidence that children are widely exposed to organophosphorus pesticides (OPs) and that OPs cause developmental neurotoxicity in animal models raises significant concerns about the risks these compounds pose to the developing human nervous system. Critical to assessing this risk is identifying specific neurodevelopmental events targeted by OPs. Observations that OPs alter brain morphometry in developing rodents and inhibit neurite outgrowth in neural cell lines suggest that OPs perturb neuronal morphogenesis. However, an important question yet to be answered is whether the dysmorphogenic effect of OPs reflects perturbation of axonal or dendritic growth. We addressed this question by quantifying axonal and dendritic growth in primary cultures of embryonic rat sympathetic neurons derived from superior cervical ganglia (SCG) following in vitro exposure to chlorpyrifos (CPF) or its metabolites CPF-oxon (CPFO) and trichloropyridinol (TCP). Axon outgrowth was significantly inhibited by CPF or CPFO, but not TCP, at concentrations > or =0.001 microM or 0.001 nM, respectively. In contrast, all three compounds enhanced BMP-induced dendritic growth. Acetylcholinesterase was inhibited only by the highest concentrations of CPF (> or =1 microM) and CPFO (> or =1 nM); TCP had no effect on this parameter. In summary, these compounds perturb neuronal morphogenesis via opposing effects on axonal and dendritic growth, and both effects are independent of acetylcholinesterase inhibition. These findings have important implications for current risk assessment practices of using acetylcholinesterase inhibition as a biomarker of OP neurotoxicity and suggest that OPs may disrupt normal patterns of neuronal connectivity in the developing nervous system.

PMID: 16102564 [PubMed - indexed for MEDLINE]

ie: measurement of acetylcholinesterase inhibition is not identifying all the methods by which OPs affect the nervous system, yet it is the current biomarker for OP toxicity. Not good enough!


Rev Environ Health. 2006 Apr-Jun;21(2):105-17.

Involvement of environmental mercury and lead in the etiology of neurodegenerative diseases.

Monnet-Tschudi F, Zurich MG, Boschat C, Corbaz A, Honegger P.
Department of Physiology, University of Lausanne, Switzerland. [email protected].

The incidence of neurodegenerative disease like Parkinson's disease and Alzheimer's disease (AD) increases dramatically with age; only a small percentage is directly related to familial forms. The etiology of the most abundant, sporadic forms is complex and multifactorial, involving both genetic and environmental factors. Several environmental pollutants have been associated with neurodegenerative disorders. The present article focuses on results obtained in experimental neurotoxicology studies that indicate a potential pathogenic role of lead and mercury in the development of neurodegenerative diseases. Both heavy metals have been shown to interfere with a multitude of intracellular targets, thereby contributing to several pathogenic processes typical of neurodegenerative disorders, including mitochondrial dysfunction, oxidative stress, deregulation of protein turnover, and brain inflammation. Exposure to heavy metals early in development can precondition the brain for developing a neurodegenerative disease later in life. Alternatively, heavy metals can exert their adverse effects through acute neurotoxicity or through slow accumulation during prolonged periods of life. The pro-oxidant effects of heavy metals can exacerbate the age-related increase in oxidative stress that is related to the decline of the antioxidant defense systems. Brain inflammatory reactions also generate oxidative stress. Chronic inflammation can contribute to the formation of the senile plaques that are typical for AD. In accord with this view, nonsteroidal anti-inflammatory drugs and antioxidants suppress early pathogenic processes leading to Alzheimer's disease, thus decreasing the risk of developing the disease. The effects of lead and mercury were also tested in aggregating brain-cell cultures of fetal rat telencephalon, a three-dimensional brain-cell culture system. The continuous application for 10 to 50 days of non-cytotoxic concentrations of heavy metals resulted in their accumulation in brain cells and the occurrence of delayed toxic effects. When applied at non-toxic concentrations, methylmercury, the most common environmental form of mercury, becomes neurotoxic under pro-oxidant conditions. Furthermore, lead and mercury induce glial cell reactivity, a hallmark of brain inflammation. Both mercury and lead increase the expression of the amyloid precursor protein; mercury also stimulates the formation of insoluble beta-amyloid, which plays a crucial role in the pathogenesis of AD and causes oxidative stress and neurotoxicity in vitro. Taken together, a considerable body of evidence suggests that the heavy metals lead and mercury contribute to the etiology of neurodegenerative diseases and emphasizes the importance of taking preventive measures in this regard.

PMID: 16898674

At an Autism conference in Calgary on January 19/07 (with many good speakers), one speaker was bold enough to mention the damaging neurotoxic effects of organophophates (OPs).

During a private conversation with this doctor, from Phoenix, AZ, she revealed to me that many of her autistic patients do no show heavy loads of mercury in their chelate profiles. They do, however, show heavy loads of uranium. She has always wondered where these patients could have possibly come into contact with uranium (they do not live near any mines). Sadly, it is probably the case that these children are being exposed to the uranium via any one, or combination of the following:

-uranium fallout from atmospheric testing (much of which took place next door in Nevada.
-uranium fallout from manufacture or testing of Depleted Uranium weapons, and other nuclear weapons.
-parents working at facilities that process uranium, store nuclear waste, or military bases where weapons are kept.

She also stated that the majority of certain types of OPs used in the USA, are used in-side households to kill bugs. The developing fetus and young brain, she stated, is particularly susceptible to the neurotoxic effects of OPs.

Are we to blindly ignore the neurotoxic effects to livestock? The methods of neurotoxicity of OPs are not limited to inhibition of acetylcholinesterase, as the first study demonstrated. Multi-factoral disease processes all depend on exposure to what, when and how much, and via which exposure route(s) (inhalation, ingestion, absorption).

The co-inciding use of OPs, at rates never used before (ie: extremely high concentrations) for the UK warble eradication program STARTING in 1982 cannot be ignored in its relationship to their massive BSE cases. Other european countries also used OPs at high concentrations during this time frame.

OPs are used to spray crops which deer and other wildlife freely wander through. While exposure alone (of a healthy animal), is not enough to cause CWD, it is a contributing factor which can push a weakened animal over the top, creating all kinds of neurotoxic damage and oxidative stress.

OPs are also used to spray fruit crops which are often located near communities. Spray drift is another method of exposure to OPs and other chemicals.

One mother at the Autism symposium who lives on an acreage stated she won't grow her own garden because she is surrounded by crop land which the farmer sprays several times a year. She is concerned the veggies in a garden would be contaminated. She should also be concerned that they are inhaling these chemicals.

I met some very interesting and hard working people at this conference. There was alot of hope for treatment of Autism with various therapies, they included: injections of methyl cobalamine (Vitamin B12), digestive enzymes and acidophilus (re-establishing the good bacteria in the gut).

When it comes down to the nitty gritty, human biology is not all that different from other mammals. Toxicity of any substance is enhanced when the proper mechanisms to deal with the chemicals, metals, oxidative stress are lacking or completely gone.
 
Dr. C. Timchalk has been very busy. He is one of many given grant money to develop radionuclide chelators; and he has just published on "test kits" that will biomonitor exposure to lead and organophosphates, in blood, saliva and urine. Sounds like a TSE test kit.

radionuclides - lead - organophosphates - biomonitor and chelate


Microanalyzer for biomonitoring lead (Pb) in blood and urine.
Anal Bioanal Chem.
2007 Jan;387(1):335-41. Epub 2006 Nov 22.
Yantasee W, Timchalk C, Lin Y.
PMID: 17119936


Development of a non-invasive biomonitoring approach to determine exposure to the organophosphorus insecticide chlorpyrifos in rat saliva/b].
Timchalk C, Campbell JA, Liu G, Lin Y, Kousba AA
Toxicol Appl Pharmacol. 2007 Mar;219(2-3):217-25. PMID: 17118418


Age-related brain cholinesterase inhibition kinetics following in vitro incubation with chlorpyrifos-oxon and diazinon-oxon.
Kousba AA, Poet TS, Timchalk C.
Toxicol Sci. 2007 Jan;95(1):147-55. PMID: 17018647


The acquisition and application of absorption, distribution, metabolism, and excretion (ADME) data in agricultural chemical safety assessments./b]
Crit Rev Toxicol. 2006 Jan;36(1):9-35. Review.
Barton HA, Pastoor TP, Baetcke K, Chambers JE, Diliberto J, Doerrer NG, Driver JH, Hastings CE, Iyengar S, Krieger R, Stahl B, Timchalk C.
PMID: 16708693


Disposition of lead (Pb) in saliva and blood of Sprague-Dawley rats following a single or repeated oral exposure to Pb-acetate.
Timchalk C, Lin Y, Weitz KK, Wu H, Gies RA, Moore DA, Yantasee W
Toxicology. 2006 May 1;222(1-2):86-94. PMID: 16510233


Potential technology for studying dosimetry and response to airborne chemical and biological pollutants.
Timchalk C, Trease HE, Trease LL, Minard KR, Corley RA.
Toxicol Ind Health. 2001 Jun;17(5-10):270-6.
PMID: 12539872

http://www.sciencedaily.com/releases/2006/09/060925163456.htm

Project Bioshield: Researchers To Develop Anti-Radiation Treatments
Science Daily — The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has issued five awards totaling $4 million to fund the development of products that eliminate radioactive materials from the human body following radiological or nuclear exposure. The awards, which were granted under Project Bioshield authorities, complement NIAID's other medical countermeasure efforts to create safe and effective products of this type.

"These new grants will help identify new drug candidates that could be acquired by the strategic national stockpile of medical countermeasures, which is available to the public after a terrorist or nuclear attack or accidental radioactive exposure," says NIAID Director Anthony S. Fauci, M.D.

In the event of an attack by a nuclear explosive device or radiological "dirty bomb," individuals potentially could inhale, ingest or absorb through their skin radioactive atoms called radionuclides. Depending on the type of radionuclide that a person is exposed to, the particles may be excreted from the body or enter bones, organs or other tissues, which could have significant adverse health consequences. Through an initiative announced in 2005, NIAID already is working to speed the development of a series of products that can bind (chelate) internally with the radionuclides and eliminate (decorporate) them from the body. Radionuclide decorporation products currently are available in the strategic national stockpile, but NIAID is focusing on expanding the product pool, creating new treatments capable of eliminating a wider range of radionuclides, developing products that can eliminate radioactive material faster and in greater amounts; and developing products in formulations that could be distributed more easily in a mass casualty situation.

NIAID has awarded five grants totaling up to $4 million to fund work for a period of 18 months. The following principal investigators and universities are the recipients of the grants:

* Raymond J. Bergeron, Ph.D., University of Florida, Gainesville, $1.0 million

* Tatiana G. Levitskaia, Ph.D., Pacific Northwest National Laboratory, Richland, WA, $725,000

* Scott C. Miller, Ph.D., University of Utah School of Medicine, Salt Lake City, $675,000

* Kenneth N. Raymond, Ph.D., University of California/Lawrence Berkeley National Laboratory, Berkeley, CA, $998,325

* Charles Timchalk, Ph.D., Pacific Northwest National Laboratory, Richland, WA, $599,747

"The goal of this new program is to accelerate the development of previously identified, promising compounds into effective products that could be licensed for use," says program officer Bert Maidment, Ph.D., associate director of product development in NIAID's Division of Allergy, Immunology and Transplantation.

NIAID issued the grants under authority provided by Project Bioshield, which was signed into law in 2004. Its enactment provided federal agencies with new tools to speed research on medical countermeasures to protect Americans against chemical, biological, radiological or nuclear attack.
 

Latest posts

Back
Top